Brandon J. DeKosky

TL;DR: HIV-1 V1V2-directed neutralizing antibodies can develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation, and provide important insights relevant to HIV-1 vaccine development.

TL;DR: Key ADE mechanisms are described and mitigation strategies for SARS-CoV-2 vaccines and therapies in development are discussed and recently published data is outlined to evaluate the risks and opportunities for antibody-based protection against Sars-Cov-2.

TL;DR: The fidelity of VH:VL pairs identified by this approach were validated and the method was used to sequence the repertoire of three human cell subsets—peripheral blood IgG+ B cells, peripheral plasmablasts isolated after tetanus toxoid immunization and memory B cells isolated after seasonal influenza vaccination.

TL;DR: A low-cost, single-cell, emulsion-based technology for sequencing antibody VH-VL repertoires from >2 × 106 B cells per experiment with demonstrated pairing precision >97%.

TL;DR: High-resolution proteomics analysis of immunoglobulin coupled with high-throughput sequencing of transcripts encoding B cell receptors to quantitatively determine the antibody repertoire at the individual clonotype level in the sera of young adults before and after vaccination with trivalent seasonal influenza vaccine reveals unanticipated insights regarding the serological response to influenza vaccination.